Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc., a biopharmaceutical company focused on psychedelic-based treatments, has successfully completed an oversubscribed private placement, raising $150 million. The funding will support Phase 3 development of CYB003, a potential treatment for Major Depressive Disorder, among other corporate purposes. The investment round attracted notable institutions, reflecting strong investor confidence in Cybin’s innovative approach to mental health.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
